— Know what they know.
Not Investment Advice

ETBI OTC

Eastgate Biotech Corp.
1W: +0.0% 1M: -10.0% 3M: -10.0% YTD: -10.0% 1Y: -10.0% 3Y: -49.1% 5Y: +170.0%
$0.00
-0.00 (-81.48%)
 
OTC · Healthcare · Medical - Pharmaceuticals · Tech Score Neutral · Power 47 · $1.0M mcap · 1.49B float · 0.0000% daily turnover · Short 53% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$1.0M
52W Range0.0001-0.003
Volume7,733,200
Avg Volume104
Beta3.42
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEORosella C. Perri
Employees2
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2014-03-05
65 Harbour Square Suite 2203Toronto, M5J 2L4Canada
Toronto, ON M5J 2L4
CA
647-692-0652
About Eastgate Biotech Corp.

EastGate Biotech Corp. is a pharmaceutical company specializing in the production and distribution of nutraceuticals. These products are rooted in natural therapies and designed for natural absorption within the body. The firm employs cutting-edge nanotechnologies to provide healthier options compared to conventional pharmaceuticals, which often lead to detrimental side effects and unforeseen issues for individuals seeking to achieve and maintain good health. Among its diverse product line are E-Drops NANO, Essential D, GluCora, VCleanzz, Cleanezze, and Warts X. EastGate Biotech's development process involves integrating product components into various nano-sized delivery systems. These systems include oil droplets (nanoemulsions), polymeric particles (nanoparticles), and complex combinations of polymers, lipids, and surfactants (such as hybrid nanoparticles, nanocapsules, and mixed micelles). The company has operational bases in prominent cities including New York, London SF, Cockfosters BP, Los Angeles, Chicago, and Las Vegas.

Recent Insider Trades

NameTypeSharesPriceDate
PERRI ROSE C 0 — 2015-01-15
PERRI ROSE C 0 — 2015-01-15
PERRI ROSE C 1,036,475 $0.04 2015-01-05
GLUSKIN ANNA E P-Purchase 1,243,750 $0.04 2015-01-05
GLUSKIN ANNA E P-Purchase 1,243,750 $0.04 2015-01-05

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms